116 results about "CHRONIC INFLAMMATIONS" patented technology

The invention discloses a nano-enzyme microneedle system for remodeling a diabetes wound microenvironment to promote healing and a preparation method of the nano-enzyme microneedle system. The nano-enzyme microneedle system comprises nano-enzyme and a microneedle carrier, the nano-enzyme is prepared by a self-assembly method and is loaded in the microneedle carrier; the microneedle carrier is composed of a hydrogel matrix and is molded into a microneedle array through 3D printing; according to the system, the nano-enzyme can be delivered to the corium layer by penetrating the cuticle of the skin through the microneedle. The traditional Chinese medicine composition has the advantages that ROS (reactive oxygen species) is efficiently removed, oxidative stress injury induced by high glucose (HG) is relieved, immune cell polarization is regulated, inflammatory factor release is regulated and controlled, the chronic inflammation state of wound surfaces is relieved, cell proliferation and migration are promoted, neovascularization is accelerated, the healing speed of the diabetic wound surfaces is obviously increased, inflammation infiltration is reduced, granulation tissue formation and collagen deposition are obviously improved, and the effect of treating diabetes mellitus is achieved. And no systemic toxicity is observed. Through the synergistic effect of resisting oxidation, resisting inflammation and promoting angiogenesis, the pathological microenvironment of the diabetic wound is effectively improved.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in tumor immunity and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture antibody is prepared by coupling a biotinylated antibody with a fluorescent microsphere coated with biotin to obtain a capture antibody coupled with a fluorescent encoding microsphere, and the detection antibody is prepared by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody to obtain a fluorescent labeled antibody; the mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect various cell factors, the sample dosage is only 25 microliters, the kit is suitable for immune monitoring of iron overload and other chronic inflammation models, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

The invention discloses a degradable slow-release drug delivery device aiming at gynecological chronic inflammation and application, the degradable slow-release drug delivery device is of a hollow column-shaped or uterus-like structure matched with a gynecological physiological structure, the diameter of a hollow cavity of the hollow column-shaped structure is 2-5mm, and an arc-shaped bulge is arranged at the top end of the uterus-like structure; by replacing the drug delivery main body structure and adjusting the length of the catheter, treatment of various chronic inflammations such as cervicitis, endometritis and annexitis can be achieved, various devices do not need to be developed, the clinical use cost is reduced, the preparation process of each component of the device is the existing mature technology, the equipment investment cost is low, and the device is suitable for large-scale industrial production.

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

Disclosed herein are compositions and methods for controlling chronic inflammation in a patient. The compositions and methods employ D6-arachidonic acid or an ester thereof (D6-AA) as an anti-inflammatory agent that provides for significant reduction in inflammatory processes. In addition. The compositions of deuterated arachidonic acid or ester thereof comprise, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

This invention relates to a vulnerary multifunctional composition, based on unripe coffee cherries (peel, mucilage, beans and silverskin), seed extract of Trigonella foenum-graecum, with one or more tissue-inducing molecules derived from the secondary metabolites of both plants. The unexpected and surprising ability of this new composition to solve the problems of chronic non-healing wounds addresses a long felt unmet need in the medical arts. Through a multifaceted approach, it combats microbial infections, reduces chronic inflammation, counters oxidative stress, enhances immune responses, promotes angiogenesis, regulates protease activity, stimulates collagen deposition, increases growth factor availability, facilitates cell migration, and prevents persistent infections. These novel integrated therapies represent a breakthrough in addressing macroscopic wound healing while targeting the underlying microscale mechanisms. This invention also relates to methods for preparing, using, and administering the multifunctional composition for timely healing in mammals with various skin lesions.

A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

This disclosure presents systems and methods for baroreflex activation therapy (BAT) to regulate inflammation by modulating autonomic nervous system activity. Electrical stimulation is delivered to one or more baroreceptors, and real-time physiological signals are monitored, including inflammatory biomarkers (e.g., TNF-α, IFN-γ, IL-1, IL-6, IL-12, CRP) and autonomic parameters such as heart rate variability (HRV). A closed-loop feedback module analyzes biomarker fluctuations and autonomic balance changes and dynamically modifies stimulation parameters, including amplitude, pulse width, frequency, and duty cycle, to suppress systemic inflammation and restore autonomic balance. In certain embodiments, multi-channel stimulation architectures and AI-driven algorithms or machine learning models analyze biomarker trends and historical patient response patterns to optimize therapy. The disclosed BAT systems and methods may be used to treat inflammatory diseases, autoimmune disorders, cancer progression, chronic inflammatory pain conditions, arrhythmias associated with inflammation, and metabolic dysfunction.

The application discloses a lactobacillus crispatus based on multiple targets to realize anti-aging effect and application of transformation of glycyrrhiza for efficiency enhancement, and belongs to the technical field of microorganisms and the technical field of medicine. The lactobacillus crispatus CCFM1362 provided in the application can ferment glycyrrhiza extract, can improve the content of glycyrrhizic acid, hemiglycyrrhizin isoflavone B, naringenin chalcone and other substances, can enhance the efficacy of glycyrrhiza extract, and can realize the effect of multiple targets for anti-aging, and the specific embodiments are as follows: (1) the content of beta-galactosidase in liver tissue is inhibited; (2) the level of aging-related secretory phenotype in liver tissue is reduced; (3) the Nrf2 related pathway is activated, and the level of oxidative stress is reduced; (4) the NF-kappa B related pathway is activated, and the level of chronic inflammation is reduced. Therefore, the lactobacillus crispatus CCFM1362 and the glycyrrhiza extract have great application prospect in the production of anti-aging products.

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and / or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK / PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

A traditional Chinese medicine composition for treating acute and chronic inflammation of the ear, nose, and throat, and its preparation method, characterized in that, by weight, it is made from the following traditional Chinese medicinal materials: 10-30 parts of Lycium chinense root bark, 8-30 parts of Gardenia jasminoides, 10-30 parts of Sanguisorba officinalis root bark, 8-25 parts of Schizonepeta tenuifolia root bark, 6-16 parts of Angelica dahurica root bark, 10-35 parts of Asparagus cochinchinensis root bark, 11-35 parts of Platycodon grandiflorus root bark, 7-46 parts of Paeonia lactiflora root bark, 8-46 parts of Rehmannia glutinosa root bark, and 5-10 parts of Oroxylum indicum root bark. 14 parts of the following ingredients are used: Astragalus membranaceus 12-50 parts, Magnolia biondii 10-30 parts, Trichosanthes kirilowii 10-35 parts, Stellaria dichotoma 5-20 parts, Imperata cylindrica 7-30 parts, Fagopyrum dibotrys 10-35 parts, Coix lacryma-jobi 13-60 parts, Lepidium apetalum 5-15 parts, Gypsum fibrosum 14-50 parts, Sophora tonkinensis 3-20 parts, Lonicera japonica 12-50 parts, Xanthium sibiricum 6-35 parts, Ephedra sinica 6-30 parts, and Styrax benzoin 1-3 parts. After grinding into powder, the mixture is steamed with rice wine to obtain pills. The principle of treating all three (ear, nose, and throat) simultaneously, considering the anatomical structure and physiological function of the ear, nose, and throat, aims to reduce cross-infection, promote recovery, and achieve ideal medicinal properties.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

Disclosed is a low-dose radiation treatment system for dementia or chronic inflammation treatment based on a photon energy beam emission form, the low-dose radiation treatment system including: a low-dose radiation therapy device wherein a treatment bed where a patient receives treatment while lying down is formed on a device body and a plurality of carbon nanotube sources are installed around an inner periphery of a ring-shaped gate of the device body to form a radiation gantry so that therapeutic radiation is irradiated toward the patient's body; and a controller configured to check a patient's condition using entered patient information and to set a treatment direction, and then to perform radiation therapy by controlling an operation of the low-dose radiation therapy device, wherein pulsed beam-type carbon nanotube sources are installed around the inner periphery of the radiation gantry, and the controller controls a radiation beam irradiation time (beam on-off time) of the carbon nanotube sources and a radiation beam irradiation interval between the carbon nanotube sources to control the radiation beam irradiation interval to a cell damage repair time (DNA repair time) of being capable of repairing DNA damage in normal cells.

This invention provides a cell microenvironment stabilizer that captures hydrogen ions, its preparation method, and its application, belonging to the field of biomedical technology. The preparation method of this cell microenvironment stabilizer includes the following steps: (1) mineralizing CaCl2 with TGF-β1, catalase, and polyethylene glycol-polyglutamic acid block copolymer to obtain mineralized nanoparticles; (2) preparing hydrogel microspheres under freezing conditions using a microfluidic device, and then photocrosslinking the frozen hydrogel microspheres; (3) mixing the hydrogel microspheres with the mineralized nanoparticles to prepare the cell microenvironment stabilizer. This invention prepares a mineralized hydrogel microsphere, which, as a cell microenvironment stabilizer, can be used to block the NLRP3 cascade in chronic inflammation, capturing excess hydrogen ions through the mineralization layer to neutralize the acidic microenvironment. This micro / nano bioreactor based on hydrogel microspheres can effectively interfere with NLRP3 in the microenvironment of degenerated tissues from inside and outside the cells, inhibiting chronic inflammation.

The present invention relates to novel compounds formed by the pairing of ion of fu- rafinitib, which have one or more improved properties compared to the prior art of furafinitib. The present invention also relates to a process for the preparation of said compounds, to pharmaceutical compositions thereof and to the use thereof for the preparation of a medicament for the treatment and / or prevention of diseases associated with abnormal angiogenesis in a patient, such as cancer, tumors, macular disorders and chronic inflammation.

This invention discloses a composition and method comprising bis(demethoxycurcumin) enriched in at least 20% w / w for inhibiting receptor for advanced glycation end products (RAGE) expression in subjects with chronic inflammatory conditions. The composition further comprises β-amyrin palmitate (BAP). This invention also discloses the use of the above composition in controlling chronic inflammatory conditions in subjects.

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and / or an inflammatory disease in an individual using such pharmaceutical compositions.

The application discloses a traditional Chinese medicine composition with the effect of treating infantile recurrent respiratory tract infection and a preparation method thereof. Through a large amount of clinical practice, the application selects radix pseudostellariae, fried atractylodes, fried rhizoma atractylodis, agastache, levisticus, lonicera, radix scrophulariae, carbonized wheat bran, calcined osseous, ephedra root as raw materials, and is prepared into an oral or external dosage form according to weight ratio. The application has the effects of transporting the spleen, preventing the invasion of pathogenic factors, and consolidating the surface and stopping sweating, and is used for infantile recurrent respiratory tract infection with the syndrome of the spleen failing to transport and the lung and defensive system failing to consolidate. The application is verified by clinical tests, has remarkable curative effect, no toxic side effect, and good safety. Animal experiment researches show that the traditional Chinese medicine composition can effectively relieve the chronic inflammation level of model mice, improve the airway epithelial barrier damage, improve the body's ability to resist pathogenic factors, and reduce the risk of infection. The application can fill the market blank of treating infantile recurrent respiratory tract infection diseases based on the theory of 'four seasons with the spleen being strong and not being invaded by pathogenic factors' and 'the spleen being strong is not about tonifying but about transportation', and has great development prospect.

The invention provides a traditional Chinese medicine composition for improving acute and chronic abdominal inflammation and a preparation method thereof. The traditional Chinese medicine composition for improving acute and chronic abdominal inflammation can improve acute and chronic abdominal inflammation by optimizing the components of the formula and the content proportioning relationship among the components, has small side effects and quick response, and inhibits the process of transforming cells into malignant cells under the stimulation of chronic inflammation.

Described herein are methods for diagnosis, screening, and treatment of autism spectrum disorder. Specifically, the invention describes methods of treating autism using dexamethasone to inhibit extracellular vesicle (EV)-mediated IFN-gamma secretion and chronic inflammation. The invention further describes methods of identifying autism in a patient by measuring EV-mediated IFN-gamma secretion in patient samples.

The invention relates to a gene-edited cytotoxic cell comprising a chimeric antigen receptor (CAR) that binds CD30, for use in the treatment of an infection, in which infected cells express CD30. In embodiments, the treatment comprises the cytotoxic cell binding to a human target cell, which is infected with a chronic inflammatory virus and expresses CD30. In embodiments, the treatment comprises cytotoxic activity against a reservoir of infected human CD30-expressing target cells in a subject with a chronic viral infection with associated pathologies, immune dysregulations and autoimmune diseases. Corresponding medical uses and methods of treatment are encompassed by the present invention. In another aspect, the invention relates to the CD30-CAR-expressing gene-edited cytotoxic cell as described herein. In other aspects, the invention relates to the CD30-CAR nucleic acid construct and the CAR polypeptide as described herein.

The purpose of the present invention is to identify a novel substance / factor relating to the anti-inflammatory activity of sugar beet, and to provide the substance / factor. This will make it possible to develop health products such as pharmaceuticals, foods and cosmetics for inhibiting chronic inflammation. Provided is a lipopolysaccharide characterized by being obtained from a bacterium that has been preserved at a preservation number of NITE BP-03839, NITE BP-03840, NITE BP-03841, NITE BP-03842, or NITE BP-03843, and a method for producing the same. The invention also provides a medicine, a medicine for animals, a quasi-medicine, a cosmetic, a food, a functional food, a feed, a fertilizer or a bath lotion additive in which the lipopolysaccharide is mixed.

The invention provides an application of OICR-9429 or a pharmaceutically acceptable salt thereof in preparation of a product for improving senescence indications. The OICR-9429 provided by the invention shows multiple beneficial technical effects in the aspect of improving senescence-related indications, not only can effectively relieve inflammatory response caused by pyroptosis in the senescence process, but also can improve the immune function and anti-infection ability of senescence organisms. The OICR-9429 also has a remarkable treatment effect on sepsis, the increase of the inflammation level caused by infection is inhibited, the survival rate of old patients is increased, and the prognosis is improved. Long-term intervention of the OICR-9429 can continuously relieve the chronic inflammation state of an aging body, increase the muscle mass, enhance the exercise ability, prolong the life and reduce various lesions accompanied by aging. The invention lays a foundation for developing products for comprehensively intervening aging and related function decline, and has important application value in the aspect of improving the life quality of old people.

The invention discloses flaxseed and wheat oligopeptide mixed powder with an effect of improving sarcopenia, and belongs to the field of biological medicines. The invention relates to a composition with an effect of improving sarcopenia. The composition comprises active ingredients including wheat oligopeptide and flaxseed meal, wherein the flaxseed powder contains secoisolariciresinol diglucoside, and a mixture of small molecules with the molecular weight smaller than 1000 Da in the wheat oligopeptide accounts for 90% or above. The invention discloses a differentiated molecular path on which the two components play roles, the wheat oligopeptide has outstanding effects in the aspects of remarkably activating a PI3K / Akt pathway and promoting FOXO3a phosphorylation inactivation, the mechanism complementarity of'upstream regulation 'and'downstream blocking' lays a solid theoretical foundation for realizing a more comprehensive anti-atrophy effect through combined use, and the wheat oligopeptide has a good application prospect. And a composite scheme with a fuzzy mechanism in the prior art is exceeded. In addition, the formula disclosed by the invention can also improve the in-vivo environment which is not beneficial to muscle maintenance from the source by relieving chronic inflammation and oxidative stress.

The embodiment of the invention discloses a bioactive peptide with an oral cavity anti-aging effect and application of the bioactive peptide. A series of experiments prove that the bioactive polypeptides IR-11 and PK-11 have remarkable anti-inflammatory efficacy, barrier repair efficacy and anti-oxidation and anti-aging efficacy, can be applied to prevention or treatment of chronic inflammatory oral diseases and oral weakness symptoms represented by periodontitis, and show good development and application prospects.

The present invention relates to an inhibitor of CD74 protein activity or expression, for the therapeutic use thereof in the prevention and / or treatment of chronic inflammatory diseases including: chronic inflammatory rheumatisms, chronic inflammatory dermatoses, chronic inflammatory bowel diseases and chronic inflammatory neurological diseases. In another embodiment, the invention relates to an isolated anti-CD74 antibody or fragment thereof, comprising six CDRs having the sequences SEQ ID NO. 3, 4, 5, 11, 12, and 13.

The invention provides an oral liquid based on algal oil-curcumin synergistic anti-inflammation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The oral liquid comprises the following raw materials: an anti-inflammatory agent (consisting of algae oil and curcumin), a traditional Chinese medicine extract (consisting of a herba houttuyniae extract and an Indian kalimeris herb extract), phospholipid, fructo-oligosaccharide, an antioxidant, a stabilizer (consisting of Arabic gum and hydroxypropyl-beta-cyclodextrin) and a flavoring agent. Experimental results show that the anti-inflammatory oral liquid is high in stability, and the content of inflammatory factors in mice with LPS-induced chronic inflammation can be remarkably reduced. The oral liquid can relieve chronic inflammation symptoms by regulating immune cell functions, blocking inflammation signal channels and other multi-target mechanisms, is high in safety after being used for a long time, does not have obvious adverse reaction, and provides a new choice for clinical treatment of chronic inflammatory diseases.

The invention belongs to the technical field of biological medicines, and relates to application of (+)-Sparteine (SPA) or pharmaceutically acceptable salts thereof in preparation of medicines for preventing, relieving or treating hepatic fibrosis. The invention proves that (+)-Sparteine can activate natural killer (NK) cells in a chronic inflammatory fibrosis environment and enhance adhesion and cytotoxic effects of the (+)-Sparteine on activated hepatic stellate cells (HSCs), so that serum biochemical indexes (AST, ALT and total bilirubin) of mice with hepatic fibrosis are remarkably improved, and collagen deposition of hepatic tissues is reduced. The invention provides a new strategy and a molecular target for the treatment of hepatic fibrosis.